Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($0.28), $0.32 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $24.02 million versus the consensus estimate of $13.1 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.